Legend Biotech：LB2501 clinical data were disclosed.
On June 2, 2026, Legend Biotech announced today that it will present, for the first time, preliminary clinical data for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy LB2501 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) at the European Hematology Association (EHA) Congress, to be held from June 11 to 14, as a Late-Breaking Oral Presentation.
LB2501 is an in vivo CD19/CD20 dual-targeting CAR-T therapy constructed using the TaVec™ platform, a proprietary lentiviral vector genetically engineered to enhance T cell specificity, transduction efficiency, and safety while limiting non-T cell transduction. Since last year, M&A activity in the in vivo CAR-T field has accelerated, with major biopharmaceutical companies entering the space and acquiring emerging R&D players. This year is expected to be a pivotal year for the therapy, as several companies are set to disclose IIT clinical data milestones.
Both Legend Biotech and Kelonia have made a strong start with 100% ORR. Whether the development of in vivo CAR-T can replicate the excitement seen in the traditional CAR-T field a decade ago remains to be seen.
Buy LB2501 online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
